Philipson Says 1-Year Faster FDA Reviews Could Unlock $10 Trillion and Speed Treatments
Updated
Updated · Fox News · Jun 1
Philipson Says 1-Year Faster FDA Reviews Could Unlock $10 Trillion and Speed Treatments
1 articles · Updated · Fox News · Jun 1
$10 trillion in economic value could be created by cutting FDA effectiveness-review timelines by one year, according to a new report by economist Tomas Philipson.
About a decade now passes from drug development to approval, Philipson said, with most of that time spent proving effectiveness rather than safety.
Faster approvals by 1 to 6 years could bring drugs, biologics and devices to patients sooner, while also lowering prescription costs by increasing competition among manufacturers.
The report urges wider use of AI in reviews, faster clinical-trial designs and broader right-to-try access, and warns China's cheaper, quicker trial system could pull investment from the U.S.
As drug approvals get faster, what protects patients from the next ineffective or harmful blockbuster?
With the FDA now demanding live trial data, is the era of lengthy drug development over?
Can insuring clinical trials finally solve biotech's high-risk funding problem?
Unlocking $4–$61 Trillion: The Economic and Global Impact of Accelerating FDA Drug and Device Approvals
Overview
Delays in the FDA approval process for medical products like drugs and devices come with a significant economic cost. Shortening development times by just one to six years could unlock trillions of dollars in value for both consumers and producers. Each year of delay means a substantial loss, calculated by multiplying total US sales by factors representing consumer and producer benefits. These delays not only limit patient access to life-saving treatments but also reduce incentives for manufacturers to innovate. The report highlights how faster approvals could benefit patients, drive innovation, and boost the economy.